Protection effects of Sigmart for no-reflow or myocardial reperfusion injury after undergoing PCI surgery

摘要

Objective:To study the protection effects of Sigmart for lack of reflow or myocardial myocardial reperfusion injury after undergoing PCI surgery.Methods: A total of 150 patients undergoing PCI surgery were selected and divided into control group and observation group with 75 cases in each group. After undergoing the surgery, both groups were given low molecular heparin 4 100 IU for 3 d, 100 mg + aspirin + atorvastatin 20 mg + clopidogrel 75 mg. 5 mL of blood specimen were collected for detection of troponin I (TnI), myocardial enzyme spectrum (CK, CK-MB) level to evaluate myocardial myocardial reperfusion injury after undergoing PCI surgery. Also electrocardiogram (ECG) were detected. Six months after the surgery, effects of Sigmart for lack of reflow or myocardial myocardial reperfusion injury after undergoing PCI surgery were evaluated.Results: 1, 6, 12, 24 h after the surgery, TnI, Mb, CK-Mb levels of were significant different from those before undergoing the surgery, and these levels of the observation group were significant higher than that of the control group. ST segment elevation at 2, 12, and 24 h after undergoing the surgery were significant obvious than that of the control group. According to the follow up, incidence of comprehensive end point event was significant higher than that of the control group. SAQ and SF-36 scores of the two groups were significant different. Conclusion: Sigmart shows good protection effects for lack of reflow or myocardial myocardial reperfusion injury after undergoing PCI surgery.